COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02793856
Recruitment Status : Active, not recruiting
First Posted : June 8, 2016
Last Update Posted : August 5, 2019
Chengdu MedGenCell, Co., Ltd.
Information provided by (Responsible Party):
You Lu, Sichuan University

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : August 20, 2018
Estimated Study Completion Date : January 31, 2020
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 April 25, 2020
May 11, 2020
2 May 12, 2020
May 21, 2020

Publications automatically indexed to this study by Identifier (NCT Number):